The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Diagnosis and treatment of Parkinson disease: molecules to medicine
Open accessAbstract
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder that affects at least 1% of people by age 70 (1-3).James Parkinson provided the first detailed description of the disease in his 1817 monograph "An Essay on the Shaking Palsy."In the latter part of the nineteenth century, Charcot further refined the description of this disorder and identified the cardinal clinical features of PD including rest tremor, rigidity, balance impairment, and slowness of movement (reviewed in ref. 4).An early clue to the pathology of the disease came from Brissaud, who speculated that damage in the substantia nigra (SN) might lead to PD (5, 6).Eosinophilic inclusions (Lewy bodies) later were identified in the brains of PD patients (7) and, along with abnormalities in the SN, became a recognized pathologic marker of the disease (8).A major advance in the understanding of PD came when dopamine deficiency was discovered in the corpus striatum and SN of brains taken from patients (9).Later studies demonstrated the connection between the SN and the striatum, thus suggesting that dopaminergic cell loss in the SN directly leads to dopaminergic deficiency in the striatum (10).The determination that PD is a disease of dopamine loss led to the development of ratio-nal therapies aimed at correcting this deficiency (11).After some initial uncertainty, the dopamine precursor levodopa proved to be a powerful PD treatment (12).Subsequent advances in therapy included combining levodopa with a peripheral decarboxylase inhibitor, such as carbidopa or benserazide (13, 14).This combination significantly reduced the nausea and vomiting associated with levodopa therapy and allowed a greater proportion of levodopa to enter the brain.Similarly, catechol-O-methyltransferase (COMT) inhibitors, which prolong the half-life of levodopa and dopamine were found to enhance the effect of a given levodopa dose (15-17).In addition to increasing the level of dopamine precursors, the focus of therapeutic design was also on limiting the breakdown of endogenous dopamine.The monoamine oxidase type B (MAO-B) inhibitor selegiline works in this fashion and provides symptomatic benefit (18).Finally, the development of dopamine agonists that directly stimulate postsynaptic dopamine receptors, thus bypassing dopamine synthesis completely, further illustrates how novel therapies can be borne from knowledge of pathology (19,20).Surgical therapies that reduce tremor and rigidity in PD patients were used prior to the advent of levodopa treatment.Meyers pioneered surgical lesioning procedures that targeted symptoms and spared patients from the hemiparesis that resulted from earlier surgical approaches.These procedures largely were abandoned once levodopa therapy became more common (21).Recent advances in the understanding of basal ganglia physiology and the development of new technologies has led to a reemergence of surgical PD therapies in the form of deep brain stimulation (DBS) (22,23).DBS has become increasingly common in patients whose disease is difficult to manage with medical therapy alone.Despite these landmark advances in symptomatic PD therapy, the ability of these treatments to facilitate an acceptable quality of life for the patient wanes with time.This is due to the development of motor complications including wearing-off (the Diagnosis and treatment of Parkinson disease: molecules to medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Cited by
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Self-citationA review on graphene-based nanocomposites for electrochemical and fluorescent biosensors
Krishnan, S. K., Singh, E., Singh, P., Meyyappan, M., & Nalwa, H. S. (2019) · RSC Advances · doi:10.1039/c8ra09577a · Cited by 785
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Metadata
- Authors
- Savitt, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1744-1754
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1986118996
- Cited by
- 650
- References
- 15
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and treatment of Parkinson disease: molecules to medicine. https://app.cochat.ai/papers/10.1172/jci29178
- The paper
- Savitt, J. M. (2006). Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation. https://doi.org/10.1172/jci29178
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.